Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase III Study of ASP7374 -Approved Egg-derived Vaccine Controlled, Double-blind, Parallel Group Study in Elderly Subjects

NCT01767896 is registered in ClinicalTrials.gov with UMN Pharma Inc. as lead sponsor.

NCT NCT01767896
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01767896 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase III Study of ASP7374 -Approved Egg-derived Vaccine Controlled, Double-blind, Parallel Group Study in Elderly Subjects
Lead sponsor
UMN Pharma Inc.
Phase
Phase 3
Overall status
Completed
Start date
October 31, 2012
Completion date
March 31, 2013
Enrollment
1,020 (actual)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

influenza